CoChat

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial

Open access

Abstract

Background Neovascular, or wet, age-related macular degeneration causes central vision loss and represents a major health problem in elderly people, and is currently treated with frequent intraocular injections of anti-VEGF protein. Gene therapy might enable long-term anti-VEGF therapy from a single treatment. We tested the safety of rAAV.sFLT-1 in treatment of wet age-related macular degeneration with a single subretinal injection. Methods In this single-centre, phase 1, randomised controlled trial, we enrolled patients with wet age-related macular degeneration at the Lions Eye Institute and the Sir Charles Gairdner Hospital (Nedlands, WA, Australia). Eligible patients had to be aged 65 years or older, have age-related macular degeneration secondary to active subfoveal choroidal neovascularisation, with best corrected visual acuity (BCVA) of 3/60-6/24 and 6/60 or better in the other eye. Patients were randomly assigned (3:1) to receive either 1 × 10(10) vector genomes (vg; low-dose rAAV.sFLT-1 group) or 1 × 10(11) vg (high-dose rAAV.sFLT-1 group), or no gene-therapy treatment (control group). Randomisation was done by sequential group assignment. All patients and investigators were unmasked. Staff doing the assessments were masked to the study group at study visits. All patients received ranibizumab at baseline and week 4, and rescue treatment during follow-up based on prespecified criteria including BCVA measured on the Early Treatment Diabetic Retinopathy Study (EDTRS) sca…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)00345-1

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Cited by

See all 190

Metadata

Authors
Rakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., & Constable, I. J.
Affiliations
  • Lions Eye Institute (AU)
  • The University of Western Australia (AU)
  • University of California, Los Angeles (US)
  • Stanford University (US)
Corresponding author
Rakoczy, Elizabeth P
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-12
Volume
386
Issue
10011
Pages
2395-2403
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W1755815992
Cited by
189
References
53
Citations by year
2026: 9 · 2025: 7 · 2024: 20 · 2023: 14 · 2022: 15 · 2021: 26 · 2020: 19 · 2019: 13 · 2018: 23 · 2017: 29 · 2016: 11 · 2015: 2
FWCI
20.80
Type
journal article
Language
en
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
Funders
  • Oregon Lions Sight and Hearing Foundation
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
neovascular age-related macular degeneration, gene therapy, recombinant adeno-associated virus, soluble fms-like tyrosine kinase-1, subretinal injection, choroidal neovascularization, ranibizumab, anti-VEGF therapy, treatment safety, visual acuity, anti-angiogenic therapy
MeSH terms
Ranibizumab, Adenoviridae, Aged, Aged, 80 and over, Female, Genetic Vectors, Humans, Male, Recombinant Proteins, Visual Acuity, Genetic Therapy, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor Receptor-1, Injections, Intraocular, Wet Macular Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. https://app.cochat.ai/papers/10.1016/s0140-6736(15)00345-1
The paper
Rakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., & Constable, I. J. (2015). Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. The Lancet. https://doi.org/10.1016/s0140-6736(15)00345-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.